The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Real-world FIL-MAB data support frontline Pola-R-CHP in DLBCL
Marco Ladetto, MD, Antonio e Biagio e Cesare Arrigo Hospital, Alessandria, Italy, discusses the primary analysis of the polatuzumab vedotin plus R-CHP (Pola-R-CHP) cohort from FIL-MAB (NCT06008691), a prospective, multicenter Italian real-world study. He highlights findings from one of the largest real-life evaluations of frontline Pola-R-CHP in diffuse large B-cell lymphoma (DLBCL), demonstrating encouraging effectiveness, a manageable safety profile, and broad applicability across both academic and community treatment centers. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well, the FIL-MAB is a large prospective observational study conducted in Italy that will investigate all the new monoclonal antibodies containing regimens in the real-life world, including more than 90 different centers across Italy. And therefore, the whole study has already enrolled at almost 1,000 patients. And the most numerous cohort at the moment is the Pola-R-CHP cohort that investigates the use of Polatuzumab in first-line treatment for diffuse large B-cell lymphoma patients...
Well, the FIL-MAB is a large prospective observational study conducted in Italy that will investigate all the new monoclonal antibodies containing regimens in the real-life world, including more than 90 different centers across Italy. And therefore, the whole study has already enrolled at almost 1,000 patients. And the most numerous cohort at the moment is the Pola-R-CHP cohort that investigates the use of Polatuzumab in first-line treatment for diffuse large B-cell lymphoma patients. These patients, we were able to provide a preliminary overview on this cohort, including almost 170 patients. And the results in this population that clearly appear much worse compared to the one of the clinical trials indicates that the Pola-R-CHP treatment is feasible, is effective with PFS and complete response rate, which are basically comparable to what we would have expected for this kind of population. We also did some preliminary emulation approach that indicated, again, the good efficacy of the regimen. In terms of toxicity, we did not record special events or special extra toxicity that were not previously recorded in the clinical trial, indicating that this approach has a wide applicability. Also, in small institutions, because our study included both large academic centers, but also several small community hospitals, And that is, again, very important, I think, to provide, to generate an idea of what can Pola-R-CHP give to the standard European population with Diffuse Large B-cell Lymphoma. Thank you.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
